Biologics in India: bridging the gap

Section 10(4)(ii)(D) of India’s Patents Act, 1970 mandates the disclosure of the source and geographical origin of biological material whenever it’s mentioned in a patent specification but not sufficiently described in it or made available to the public.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

USPTO director steps into Sun Pharma’s PTAB-ITC clash

31 July 2026 A director review has overturned a PTAB ruling, questioning why it diverged from an ITC decision based on the same patent claims, prior art and evidence.

Careers

USPTO appoints new acting commissioner for patents

31 July 2026 The ex-Greenberg Traurig shareholder will oversee the office’s 14,000-strong patent division, as the agency prepares for the departure of deputy director Coke Morgan Stewart.

MedTech

European court strikes down hearing aid sensor patent

30 July 2026 A dispute over optical sensor technology in miniature hearing devices ended with the EPO revoking a patent, finding the invention obvious despite ruling it was new over the closest prior art.

More features

Trump slaps 100% tariff on generic drugs in US manufacturing push

Pharmascience v Janssen: Canada court updates methods of medical treatment protection

‘Blatant imitation’: Indian court blocks copycat pharma branding

US life sciences damages averaged $33.5m between 2019-2025

Chadha & Chadha hires former Remfry & Sagar patent partner

Patent office fee increases: What applicants must know

IndiaMart v CDSCO: A test of intermediary liability

Part I: Ozempic goes generic as Novo’s key patent expires

Biologics in India: bridging the gap

More on this story

Editor's picks

Editor's picks

More features